Page last updated: 2024-12-05

lormetazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13314
CHEMBL ID22097
CHEBI ID52993
SCHEMBL ID43267
MeSH IDM0081520

Synonyms (55)

Synonym
unii-gu56c842za
gu56c842za ,
lormetazepam
2h-1,4-benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-
loramet
loretam
noctamid
zk-65997
wy-4082
dea no. 2774
lormetazepam [usan:inn:ban:jan]
ro 5-5516
7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one
brn 0759821
lormetazepamum [inn-latin]
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
n-methyllorazepam
einecs 212-700-5
wy 4082
2h-1,4-benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-
methyllorazepam
7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one
D01657
848-75-9
loramet (tn)
lormetazepam (jan/usan/inn)
chlorotemazepam
CHEMBL22097 ,
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one
(+-)-lorazepam
lormetazepamum
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
CHEBI:52993 ,
(rs)-lormetazepam
noctamide
ergocalm
(+/-)-lormetazepam
lormetazepam [who-dd]
lormetazepam [usan]
lormetazepam [jan]
lormetazepam [mart.]
lormetazepam [inn]
lormetazepam [mi]
gtpl7553
dormagen
SCHEMBL43267
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
lormetazepam 0.1 mg/ml in methanol
lormetazepam 1.0 mg/ml in methanol
()-lorazepam
DB13872
7-chloro-1,3-dihydro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one
DTXSID40862442
Q186257
lormetazepam, 1mg/ml in acetonitrile

Research Excerpts

Overview

Lormetazepam is a short-acting benzodiazepine hypnotic which is beneficial in shortening the time to onset of sleep. It was found to be an effective hypnotic that causes virtually no hangover the next morning.

ExcerptReferenceRelevance
"Lormetazepam is a short-acting benzodiazepine hypnotic which is beneficial in shortening the time to onset of sleep. "( A randomized clinical trial comparing doses and efficacy of lormetazepam tablets or oral solution for insomnia in a general practice setting.
Alquier, C; Ancolio, C; Blin, O; Micallef, J; Pradel, V; Soubrouillard, C; Tardieu, S, 2004
)
2.01
"Lormetazepam is a hypnotic benzodiazepine currently used in the treatment of insomnia. "( Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
Bonanni, E; Fabbrini, M; Frittelli, C; Iudice, A; Maestri, M; Manca, ML, 2005
)
2.01
"Lormetazepam (Loramet is a benzodiazepine mainly used as an hypnotic to treat insomnia. "( Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode.
Lemmer, P; Mühe, A; Schneider, S; Wennig, R, 2007
)
2.07
"Lormetazepam was found to be an effective hypnotic that causes virtually no hangover the next morning."( Lormetazepam - a benzodiazepine derivative without hangover effect? A double-blind study with chronic insomniacs in a general practice setting.
Beach, RC; Heidrich, H; Ott, H, 1981
)
2.43
"Lormetazepam is a new benzodiazepine hypnotic. "( Sleep laboratory study of lormetazepam in older insomniacs.
Vogel, GW, 1984
)
2.01

Effects

ExcerptReferenceRelevance
"Lormetazepam 1 mg has no residual sedative effects."( Lormetazepam, memory and information processing: a review.
Alford, CA; Bhatti, JZ; Hindmarch, I, 1988
)
2.44

Treatment

ExcerptReferenceRelevance
"Oral treatment with lormetazepam led to markedly lower anxiety values than treatment with placebo (p less than 0.1; t test, one-sided)."( [Preoperative anxiolysis with lormetazepam. A model for measuring anxiety].
Doenicke, A; Ott, H; Suttmann, H; Ulsamer, B, 1983
)
0.87

Toxicity

ExcerptReferenceRelevance
" Adverse reactions were evenly distributed among the LMZ and placebo treatment periods and were usually minor."( Double-blind evaluation of the safety and hypnotic efficacy of lormetazepam in general practice.
Camera, A; Gherardi, S; Maxia, D; Moja, EA; Scamonatti, L, 1983
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" After both treatments the terminal half-life of total radioactivity and lormetazepam glucuronide in plasma corresponded to the half-life of elimination in urine of about 13 hours."( The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C.
Hümpel, M; Illi, V; Kurowski, M; Milius, W; Wendt, H, 1979
)
0.73
"Clinical experience with benzodiazepines shows that observable effects like sedation do not persist as long as predicted by pharmacokinetic data."( Relationship between EEG dynamics and pharmacokinetics of the benzodiazepine lormetazepam.
Herrmann, WM; Kurowski, M; Ott, H, 1982
)
0.49
" The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation)."( Clinical pharmacokinetics of the newer benzodiazepines.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Ochs, HR; Shader, RI,
)
0.13
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability was increased in the C-group with 57-134% vs."( Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers.
Hellenbrecht, D; Hellstern, A; Hildebrand, M; Hümpel, M; Saller, R,
)
0.4
"A study was carried out to estimate the relative bioavailability of 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1, 3-dihydro-1H-1,4-benzodiazepine-2-one (lormetazepam, Minias) in humans after administration of oral tablets and solutions."( Relative bioavailability in humans for oral tablets and solutions of lormetazepam.
Ceccarelli, G; Ciampini, M; Ferrario, P; Fraschini, F; Pirola, R; Reina, L; Scaglione, F; Zecca, L, 1985
)
0.7
" Bioavailability and elimination kinetics did not differ between the formulations."( Pharmacodynamic correlates of modified absorption: studies with lormetazepam.
Franklin, RA; Harry, TV; Nicholson, AN; Pierce, DM, 1984
)
0.51
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Lormetazepam (Noctamid) at a dosage of 1 mg was compared with diazepam (Valium) in a 7-day double-blind study. Lormetzepam 1 mg produced no significant effects on objective (CFF) or subjective measures (ARS) of sedation the morning following either acute or repeated dosing.

ExcerptRelevanceReference
" Flunitrazepam, Midazolam or Lormetazepam in a higher dosage could be expected."( [Effect and side effects of oral morphine, lormetazepam and placebos as premedication].
Hartung, M; Hettenbach, A; Krug, C; Tolksdorf, W, 1987
)
0.83
" The results suggest that the extent of the benzodiazepines' amnesic effects--both negative (anterograde) and positive (retrograde)--depends on the dosage and type of substance."( Anterograde and retrograde amnesia after lormetazepam and flunitrazepam.
Aufdembrinke, B; Fichte, K; Ott, H; Rohloff, A, 1988
)
0.54
"Lormetazepam (Noctamid) at a dosage of 1 mg was compared with diazepam (Valium) at a dosage of 5 mg in a 7-day double-blind study."( Comparative efficacy of lormetazepam (Noctamid) and diazepam (Valium) in 100 out-patients with insomnia.
Fichte, K; Hentschel, HD; Sastre y Hernández, MS, 1981
)
2.01
"Lormetazepam, a new benzodiazepine derivative, was tested under double blind conditions in order to find the optimal dosage for different age groups of out-patients."( Age-specific doses of lormetazepam as a night sedative in cases of chronic sleep disturbance.
Heidrich, H; Jovanović, UJ; Ott, H; Schratzer, M; Stephan, K,
)
1.89
" There was no dose-response effect for efficacy for either the first three or last three nights of this short-term administration period."( Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia.
Bixler, EO; Kales, A; Kales, JD; Mitsky, DJ; Soldatos, CR,
)
0.43
" Lormetazepam 1 mg produced no significant effects on objective (CFF) or subjective measures (ARS) of sedation the morning following either acute or repeated dosing and had no effects on subjective ratings of sleep and early morning behaviour."( The effects of lormetazepam on aspects of sleep and early morning performance.
Hindmarch, I; Subhan, Z, 1983
)
1.53
" The findings in the present study clearly indicate that the plasma profiles of lormetazepam attained on sublingual and oral dosing are similar, indeed the pharmacokinetic characteristics of this drug appear identical being independent of its route of administration."( Lormetazepam--plasma concentrations in volunteers following sublingual and oral dosing.
Luscombe, DK, 1984
)
1.94
" The EEG is a proven parameter with regard to dosage determination and as objective means to find sleep-inducing quantities of drugs."( Modern trends in the investigation of new hypnotics in anaesthesia.
Doenicke, A, 1984
)
0.27
" The dose-response relationship was bell-shaped."( Effects of lormetazepam on glycemia and serum lipids in hyperlipidemic rats.
Cuparencu, B; Horák, A; Horák, J; Lenghel, A,
)
0.52
" The primary study variables were visual simple reaction time (VSRT) and visual choice reaction time (VCRT), measured before dosing with lormetazepam or placebo and at 20, 60, 120, 180, 240, and 360 minutes after dosing using a standard computerized apparatus."( Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
Bonanni, E; Fabbrini, M; Frittelli, C; Iudice, A; Maestri, M; Manca, ML, 2005
)
0.77
" After administration of placebo, 1 subject reported slight somnolence 60 minutes after dosing that persisted through 180 minutes."( Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
Bonanni, E; Fabbrini, M; Frittelli, C; Iudice, A; Maestri, M; Manca, ML, 2005
)
0.56
" Socio-demographic (more women; higher age and education) and clinical features (higher daily diazepam dosage equivalent, BZD abuse duration, age of first BZD intake; BZD prescribed more frequently for sleep disorders; less frequent history of other SUDs, previous/active alcohol, previous opioids abuse; more frequent overall major psychiatric diseases and major depression; less-frequent bipolar disorders and other psychoses, personality disorders, and more than one psychiatric disease) of LMZ vs."( High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde.
Casari, R; Faccini, M; Lugoboni, F; Morbioli, L; Tamburin, S, 2019
)
0.92
" A 30-year-old female elite athlete developed lormetazepam addiction after increasing her daily benzodiazepine dosage in an attempt to achieve better sleep and enhanced performances during training."( Benzodiazepine abuse among athletes: Pain relief or just a weapon against insomnia? A clinical case study.
Lugoboni, F; Zamboni, L; Zandonai, T, 2019
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1,4-benzodiazepinone
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID194131ED50 value was reported as log1/C, which is the concentration required to reduce locomotor activity by 50% in rats1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID23479Partition coefficient (logP)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID194134Halving of lever pressing in non punished rats, ED50 value reported as log 1/C1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID194132Fourfod increase in lever pressing in punished rats, ED50 value reported as log1/C1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (179)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990110 (61.45)18.7374
1990's23 (12.85)18.2507
2000's24 (13.41)29.6817
2010's15 (8.38)24.3611
2020's7 (3.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.28 (24.57)
Research Supply Index5.62 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index149.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials83 (43.46%)5.53%
Reviews7 (3.66%)6.00%
Case Studies15 (7.85%)4.05%
Observational0 (0.00%)0.25%
Other86 (45.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week,Randomized, Double-blind, Comparative, Parallel-group Study. [NCT00788515]Phase 333 participants (Actual)Interventional2008-11-30Terminated(stopped due to Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary insomnia with predominant sleep maintenance problems)
Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care [NCT02022592]Phase 484 participants (Actual)Interventional2014-07-17Completed
Comparison of the Safety and Efficacy of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week, Randomized, Double-blind,Comparative, Parallel-group Study [NCT00679900]Phase 3283 participants (Actual)Interventional2008-04-30Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
The Effect of Lormetazepam Versus Midazolam in Critically Ill Patients on Hospital Mortality: a Retrospective Cohort Trial [NCT04408911]3,314 participants (Actual)Observational2006-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]